The comparative effects of medical therapies for Parkinson's disease.
Horn
Stacy
S
Parkinson's Disease and Movement Disorders Center, Penn Neurologic Institute, University of Pennsylvania, 330 South 9 Street, Philadelphia, PA 19107, USA. horns@pahosp.com
Stern
Matthew B
MB
D000978:Antiparkinson Agents / Q000145:classification / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018491:Dopamine Agonists / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents